Drug Profile


Alternative Names: AVE 7688

Latest Information Update: 11 Aug 2008

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class 3-ring heterocyclic compounds; Antihypertensives; Heart failure therapies; Small molecules
  • Mechanism of Action ACE inhibitors; Neprilysin inhibitors; Vasopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic nephropathies; Heart failure; Hypertension

Most Recent Events

  • 31 Jul 2008 Discontinued - Phase-II for Hypertension in France (PO)
  • 31 Jul 2008 Discontinued - Phase-II for Diabetic nephropathies in France (PO)
  • 31 Jul 2008 Discontinued - Phase-I for Congestive heart failure in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top